At a glance
ClinicalIndex Comparison RecordN/ACompleted· 228 enrolled
Drug / intervention
sentinel node biopsy and mastectomyprocedure
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Management of Ductal Carcinoma in Situ (DCIS) or Pure Micro-invasive (DCIS-MI) Extended Breast, Axillary Node Sentinel Site (GAS) When the Diagnosis is Made by Biopsy and Treatment by Mastectomy Immediately. Descriptive Study
In Brief
An observational study evaluating sentinel node biopsy and mastectomy for Intraductal Carcinoma and Lobular Carcinoma in Situ. Completed, enrolled 228 participants across 1 site.
Detailed Summary
When invasive components are discovered at mastectomy for vacuum-assisted biopsy (VAB)-diagnosed ductal carcinoma in situ (DCIS), the only option available is axillary lymph node dissection (ALND). The aim of this prospective multicenter trial was to determine the benefit of performing upfront sentinel lymph node (SLN) biopsy for these patients.
Study Details
Study Typeobservational
Allocation--
Masking--
Primary Purpose--
CountriesFrance
Collaborators--
Timeline
N/ACompletedFinished
20082009201020112012201320142015201620172018201920202021202220232024202520262027
Enrollment StartJan 2008
Primary CompletionDec 2010
First PostedApr 2013
TodayJul 2026
First PostedApr 26, 2013
Enrollment StartJan 1, 2008
Primary CompletionDec 1, 2010
TodayJul 2, 2026
Enrollment to primary: 2.9 yearsPosted 13.2 years ago
Interventions
sentinel node biopsy and mastectomyprocedure
sentinel node biopsy and mastectomy